Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

The anti-inflammatory injection, also known as adalimumab, lost its U.S. market exclusivity in early 2023 after generating hundreds of billions of dollars in sales for AbbVie (NYSE:ABBV ...

possible malignancies and COPD exacerbation Adalimumab (Humira®) Injection site reactions and upper respiratory tract infections Serious bacterial infections, unusual infections (tuberculosis and ...

The anti-inflammatory injection, also known as adalimumab, lost its U.S. market exclusivity in early 2023 after generating hundreds of billions of dollars in sales for AbbVie (NYSE:ABBV ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

Montrealer Michael Santillo was 29 when he was diagnosed with ankylosing spondylitis, a type of inflammatory arthritis. It ...

AbbVie's dividend growth has subsided in recent years because of the loss of patent-protected market exclusivity for its former lead product, Humira. Sales of the popular injection used for ...

Humira is a versatile drug used to treat multiple ... designed to decrease injection volume for higher doses and also reduce pain at the injection site. The high-concentration version currently ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... aiming to cut injection volume by half and result in fewer injections in particular patients.